Barbara Burtness MDAnthony N. Brady Professor of Medicine; Chief Translational Research Officer; Associate Director, Translational Science; Division Chief, Head and Neck/Sarcoma Oncology; Co-Leader, Developmental Therapeutics Program; Director, Yale Head and Neck SPORE, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
Dr. Barbara Burtness is Anthony N. Brady Professor of Medicine at the Yale University School of Medicine. She is founding director of the Yale Head and Neck SPORE, co-leader of the Developmental Therapeutics Program, and director of the Head and Neck Clinical Research Program at Yale Cancer Center. Dr. Burtness graduated with an MD from SUNY at Stonybrook. She completed internship and residency at Yale-New Haven Hospital and fellowship training in oncology at Memorial Sloan Kettering Cancer Center.
Dr. Burtness' research focuses on clinical trials of immunotherapy and translational studies of resistance to immunotherapy and EGFR inhibition, and synthetic lethal approaches for HPV negative head and neck cancer. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multi-center trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers, and co-leads the Stand Up to Cancer Head and Neck Cancer Team. She has conducted numerous phase I–III investigator-initiated trials.
Dr. Burtness co-edits the text Molecular Determinants of Head and Neck Cancer. Her research has been published in numerous peer-reviewed journals, including the Lancet, Journal of Clinical Oncology, Lancet Oncology, and Clinical Cancer Research.
Honoraria/Consulting/Data Safety Monitoring Boards:
AbbVie, ALX Oncology, Astra Zeneca, Coherus, Cue Biopharma, Eisai, Glaxo Smith Kline, IMS Consulting, IO Biotech, Kura, Merck KgA, Merck, Merus, Orphagen, Vaccinex, Slingshot, Surface
Recent Contributions to PracticeUpdate:
- Immunochemotherapy as a Single Treatment for Larynx Preservation
- Durvalumab Added to First-Line Carboplatin/Paclitaxel for Recurrent/Metastatic HNSCC
- Adjuvant Chemotherapy for Nasopharynx Cancer
- Final OS Analysis of JUPITER-2: Incorporation of ICI in the First Line for Recurrent/Metastatic Nasopharyngeal Cancer
- PD-1 Blockade Plus Induction Chemotherapy and Concurrent Chemoradiation for Locally Advanced Nasopharynx Cancer
- 2022 Top Story in Oncology: Nivolumab/Ipilimumab in First-Line for Recurrent/Metastatic HNSCC—CheckMate 651
- Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT
- Phase III KEYNOTE-412: Pembrolizumab With Chemoradiation Therapy vs Placebo Plus CRT for Locally Advanced HNSCC
- Phase VI KEYNOTE-B10: Pembrolizumab Plus Carboplatin Plus Paclitaxel as First-line Therapy in R/M HNSCC
- ESMO 2022: Recommendations From Dr. Barbara Burtness for Head and Neck Cancer